IJS's Underlying Holdings Could Mean 21% Gain Potential
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 03 2025
0mins
Source: NASDAQ.COM
ETF Analysis: The iShares S&P Small-Cap 600 Value ETF (IJS) has an implied analyst target price of $131.20, indicating a potential upside of 21.32% from its current trading price of $108.14.
Stock Performance Insights: Notable underlying holdings such as Concentra Group Holdings, Adient plc, and Penguin Solutions show significant upside potential based on analysts' target prices, raising questions about the validity of these targets amidst market developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CON
Wall Street analysts forecast CON stock price to fall
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 31.840
Low
27.00
Averages
28.67
High
30.00
Current: 31.840
Low
27.00
Averages
28.67
High
30.00
About CON
Concentra Group Holdings Parent, Inc. is a provider of occupational health services in the United States. It delivers an extensive suite of services, including occupational and consumer health services and other direct-to-employer care, to more than 53,000 patients each day, on average, from about 682 occupational health centers in 41 states and 411 onsite health clinics at employer worksites in 44 states. Its Occupational Health Centers segment encompasses the services it delivers at its occupational health center facilities across the United States. Its Onsite Health Clinics segment delivers occupational health services and/or employer-sponsored primary care services at an employer's workplace, including mobile health services and episodic specialty testing services. Its Other Businesses segment comprises several complementary services to its core occupational health services offering and includes Concentra Telemed, Concentra Pharmacy and Concentra Medical Compliance Administration.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Latest Wall Street Rating Updates
- Abbott Labs Upgrade: Baird initiates coverage on Abbott Labs (ABT) with an outperform rating, projecting steady revenue and earnings growth of 6-8% over the next few years, bolstered by its leading position in the rapidly growing MedDevice market, enhancing the company's competitive edge.
- Murphy USA Upgrade: Jefferies upgrades Murphy USA (MUSA) from hold to buy, citing improving fuel margins that are expected to drive EBITDA outlook significantly higher by 20-25%, which will materially enhance the company's financial performance in the coming years.
- Abivax Upgrade: Jefferies raises Abivax (ABVX) to buy, noting strong data for its ulcerative colitis drug that alleviates key market concerns, which is likely to drive a rebound in the stock price.
- Talos Energy Upgrade: Roth upgrades Talos Energy (TALO) from neutral to buy, raising the price target by 6% to $17, based on its robust balance sheet and low production decline rates, indicating strong future growth potential.
See More
Latest Ratings and Outlook from Wall Street
- Qualcomm Investor Day: Qualcomm is set to host its highly anticipated Investor Day on June 24, discussing growth and diversification strategies in the rapidly evolving AI landscape; JPMorgan maintains a neutral rating but remains optimistic about future performance.
- Nvidia Buy Reiteration: Bank of America reiterates its buy rating on Nvidia after a meeting with management, highlighting the stock's strong performance across the board, particularly following the positive outlook shared during the GTC Taipei conference.
- Tesla Rating Upgrade: JPMorgan upgrades Tesla from underperform to neutral, citing its unique vertical integration across hardware and software products, which positions the company favorably for scaling in the industry.
- Disney Price Target Increase: Rosenblatt raises Disney's price target from $121 to $126, based on optimistic projections for its movie slate, particularly with the upcoming release of Toy Story 5, which is expected to drive earnings growth.
See More
Concentra Group Holdings Reports Strong Q1 2026 Earnings and Raises Guidance
- Significant Revenue Growth: Concentra Group reported total revenue of $569.6 million in Q1 2026, reflecting strong performance in the workers' compensation sector, which is expected to further enhance overall financial health and stability.
- Increased Patient Visits: The company experienced a 6.7% increase in patient visits, averaging over 54,000 per day, indicating ongoing improvements in customer satisfaction and market share, thereby strengthening its competitive position in the healthcare services market.
- Upgraded Full-Year Outlook: CFO DiCanio raised the 2026 revenue guidance by $25 million to a range of $2.275 billion to $2.375 billion, along with an adjustment in EBITDA expectations, showcasing the company's confidence in future performance and robust market demand.
- Leadership Transition Plan: Chief Medical Officer John Anderson announced his retirement at the end of the year, prompting Concentra to evaluate both internal and external candidates to ensure a smooth leadership transition, thereby reinforcing the company's long-term strategic direction.
See More
Concentra Group Raises 2026 Financial Guidance Following Strong Q1 Results
- Strong Performance: Concentra Group reported a Q1 non-GAAP EPS of $0.40, beating expectations by $0.06, which reflects the company's robust market performance and boosts investor confidence.
- Revenue Growth: The company achieved Q1 revenue of $569.6 million, exceeding market expectations by $16.11 million, indicating successful business expansion and strong market demand, thereby solidifying its market position.
- Guidance Upgrade: Concentra raised its 2026 revenue guidance to a range of $2.275 billion to $2.375 billion, with adjusted EBITDA expectations of $460 million to $480 million, demonstrating confidence in future growth and proactive strategic planning.
- Capital Expenditure Plans: The company plans to allocate $70 million to $80 million in capital expenditures for 2026, aimed at supporting its de novo expansion and M&A strategy, further enhancing its long-term growth potential.
See More
Concentra Group Holdings Declares Quarterly Dividend of $0.0625
- Quarterly Dividend Announcement: Concentra Group Holdings has declared a quarterly dividend of $0.0625 per share, consistent with previous payouts, indicating stable cash flow and profitability, which is likely to attract more investor interest.
- Dividend Payment Timeline: The dividend will be payable on June 9, with a record date of May 19 and an ex-dividend date also on May 19, ensuring that existing shareholders receive timely returns, thereby enhancing shareholder confidence.
- Consistent Dividend Record: Concentra has announced the same dividend for seven consecutive quarters, demonstrating the company's ability to maintain stable financial performance amid economic fluctuations, further solidifying its market position.
- Future Revenue Target: Concentra has set a revenue target of $2.25 billion to $2.35 billion for 2026, reflecting the company's proactive stance in expanding its de novo and M&A strategies, signaling potential for future growth.
See More
Concentra Group Reports Strong Q1 2026 Results and Raises Guidance
- Significant Revenue Growth: Concentra reported Q1 2026 revenue of $569.6 million, a 13.7% increase from $500.8 million in Q1 2025, indicating strong demand in the occupational health services sector and reinforcing its market leadership.
- Net Income Surge: The company achieved a net income of $52.3 million, up 28.7% year-over-year, demonstrating the effectiveness of its operational model and enhancing profitability, which provides a solid financial foundation for future investments and expansion.
- Increased Patient Visits: Patient visits reached 3,419,091 in Q1, averaging 54,271 visits per day, a 6.7% increase from the previous year, reflecting the company's ongoing appeal and trust among clients in the workers' compensation space.
- Optimistic Future Outlook: Concentra raised its 2026 financial guidance, expecting revenue between $2.275 billion and $2.375 billion, showcasing the company's confidence in future growth and the effectiveness of its strategic planning.
See More
Latest Wall Street Rating Updates
- Abbott Labs Upgrade: Baird initiates coverage on Abbott Labs (ABT) with an outperform rating, projecting steady revenue and earnings growth of 6-8% over the next few years, bolstered by its leading position in the rapidly growing MedDevice market, enhancing the company's competitive edge.
- Murphy USA Upgrade: Jefferies upgrades Murphy USA (MUSA) from hold to buy, citing improving fuel margins that are expected to drive EBITDA outlook significantly higher by 20-25%, which will materially enhance the company's financial performance in the coming years.
- Abivax Upgrade: Jefferies raises Abivax (ABVX) to buy, noting strong data for its ulcerative colitis drug that alleviates key market concerns, which is likely to drive a rebound in the stock price.
- Talos Energy Upgrade: Roth upgrades Talos Energy (TALO) from neutral to buy, raising the price target by 6% to $17, based on its robust balance sheet and low production decline rates, indicating strong future growth potential.
See More
Latest Ratings and Outlook from Wall Street
- Qualcomm Investor Day: Qualcomm is set to host its highly anticipated Investor Day on June 24, discussing growth and diversification strategies in the rapidly evolving AI landscape; JPMorgan maintains a neutral rating but remains optimistic about future performance.
- Nvidia Buy Reiteration: Bank of America reiterates its buy rating on Nvidia after a meeting with management, highlighting the stock's strong performance across the board, particularly following the positive outlook shared during the GTC Taipei conference.
- Tesla Rating Upgrade: JPMorgan upgrades Tesla from underperform to neutral, citing its unique vertical integration across hardware and software products, which positions the company favorably for scaling in the industry.
- Disney Price Target Increase: Rosenblatt raises Disney's price target from $121 to $126, based on optimistic projections for its movie slate, particularly with the upcoming release of Toy Story 5, which is expected to drive earnings growth.
See More
Concentra Group Holdings Reports Strong Q1 2026 Earnings and Raises Guidance
- Significant Revenue Growth: Concentra Group reported total revenue of $569.6 million in Q1 2026, reflecting strong performance in the workers' compensation sector, which is expected to further enhance overall financial health and stability.
- Increased Patient Visits: The company experienced a 6.7% increase in patient visits, averaging over 54,000 per day, indicating ongoing improvements in customer satisfaction and market share, thereby strengthening its competitive position in the healthcare services market.
- Upgraded Full-Year Outlook: CFO DiCanio raised the 2026 revenue guidance by $25 million to a range of $2.275 billion to $2.375 billion, along with an adjustment in EBITDA expectations, showcasing the company's confidence in future performance and robust market demand.
- Leadership Transition Plan: Chief Medical Officer John Anderson announced his retirement at the end of the year, prompting Concentra to evaluate both internal and external candidates to ensure a smooth leadership transition, thereby reinforcing the company's long-term strategic direction.
See More
Concentra Group Raises 2026 Financial Guidance Following Strong Q1 Results
- Strong Performance: Concentra Group reported a Q1 non-GAAP EPS of $0.40, beating expectations by $0.06, which reflects the company's robust market performance and boosts investor confidence.
- Revenue Growth: The company achieved Q1 revenue of $569.6 million, exceeding market expectations by $16.11 million, indicating successful business expansion and strong market demand, thereby solidifying its market position.
- Guidance Upgrade: Concentra raised its 2026 revenue guidance to a range of $2.275 billion to $2.375 billion, with adjusted EBITDA expectations of $460 million to $480 million, demonstrating confidence in future growth and proactive strategic planning.
- Capital Expenditure Plans: The company plans to allocate $70 million to $80 million in capital expenditures for 2026, aimed at supporting its de novo expansion and M&A strategy, further enhancing its long-term growth potential.
See More
Concentra Group Holdings Declares Quarterly Dividend of $0.0625
- Quarterly Dividend Announcement: Concentra Group Holdings has declared a quarterly dividend of $0.0625 per share, consistent with previous payouts, indicating stable cash flow and profitability, which is likely to attract more investor interest.
- Dividend Payment Timeline: The dividend will be payable on June 9, with a record date of May 19 and an ex-dividend date also on May 19, ensuring that existing shareholders receive timely returns, thereby enhancing shareholder confidence.
- Consistent Dividend Record: Concentra has announced the same dividend for seven consecutive quarters, demonstrating the company's ability to maintain stable financial performance amid economic fluctuations, further solidifying its market position.
- Future Revenue Target: Concentra has set a revenue target of $2.25 billion to $2.35 billion for 2026, reflecting the company's proactive stance in expanding its de novo and M&A strategies, signaling potential for future growth.
See More
Concentra Group Reports Strong Q1 2026 Results and Raises Guidance
- Significant Revenue Growth: Concentra reported Q1 2026 revenue of $569.6 million, a 13.7% increase from $500.8 million in Q1 2025, indicating strong demand in the occupational health services sector and reinforcing its market leadership.
- Net Income Surge: The company achieved a net income of $52.3 million, up 28.7% year-over-year, demonstrating the effectiveness of its operational model and enhancing profitability, which provides a solid financial foundation for future investments and expansion.
- Increased Patient Visits: Patient visits reached 3,419,091 in Q1, averaging 54,271 visits per day, a 6.7% increase from the previous year, reflecting the company's ongoing appeal and trust among clients in the workers' compensation space.
- Optimistic Future Outlook: Concentra raised its 2026 financial guidance, expecting revenue between $2.275 billion and $2.375 billion, showcasing the company's confidence in future growth and the effectiveness of its strategic planning.
See More
